Scleroderma Therapeutics Market, Global Outlook and Forecast 2023-2029
Report Code: KNJ1552940 No. of Pages: 101 Category: Pharmaceuticals and Healthcare
Publisher: Date of Publish:
Publisher: Date of Publish:
Scleroderma is an autoimmune, rheumatic, and chronic disease that affects the body by hardening connective tissue. Therapies include immunosuppressive drugs and, in some cases, glucocorticoids, and it is expected to the development of targeted biologics and small molecule combination therapies.
This report aims to provide a comprehensive presentation of the global market for Scleroderma Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Scleroderma Therapeutics. This report contains market size and forecasts of Scleroderma Therapeutics in global, including the following market information:
Global Scleroderma Therapeutics Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Scleroderma Therapeutics market was valued at US$ 1442.9 million in 2022 and is projected to reach US$ 1805.5 million by 2029, at a CAGR of 3.3% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The market is mainly driven by the off-label use of drugs approved for its symptomatic indications, such as rheumatoid arthritis.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Scleroderma Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Scleroderma Therapeutics Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Scleroderma Therapeutics Market Segment Percentages, by Type, 2022 (%)
Immunosuppressors
Phosphodiesterase 5 Inhibitors - PHA
Endothelin Receptor Antagonists
Prostacyclin Analogues
Calcium Channel Blockers
Analgesics
Others
Global Scleroderma Therapeutics Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Scleroderma Therapeutics Market Segment Percentages, by Application, 2022 (%)
Systemic
Localized
Global Scleroderma Therapeutics Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Scleroderma Therapeutics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Scleroderma Therapeutics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Scleroderma Therapeutics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
F. Hoffmann-La Roche AG
Bristol-Myers Squibb Company
Celgene Corporation
Argentis Pharmaceuticals, LLC
Bayer AG
Boehringer Ingelheim International GmbH
Akashi Therapeutics
Prometic Life Sciences, Inc.
Emerald Health Pharmaceuticals
Kadmon Holdings, Inc.
Seattle Genetics, Inc.
Cytori Therapeutics, Inc.
Fibrocell Science, Inc.
Chemomab
Corbus Pharmaceuticals Holdings, Inc.
Genkyotex
Outline of Major Chapters:
Chapter 1: Introduces the definition of Scleroderma Therapeutics, market overview.
Chapter 2: Global Scleroderma Therapeutics market size in revenue.
Chapter 3: Detailed analysis of Scleroderma Therapeutics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Scleroderma Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Scleroderma Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Scleroderma Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Scleroderma Therapeutics Overall Market Size
2.1 Global Scleroderma Therapeutics Market Size: 2022 VS 2029
2.2 Global Scleroderma Therapeutics Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Scleroderma Therapeutics Players in Global Market
3.2 Top Global Scleroderma Therapeutics Companies Ranked by Revenue
3.3 Global Scleroderma Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Scleroderma Therapeutics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Scleroderma Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Scleroderma Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Scleroderma Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Scleroderma Therapeutics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Scleroderma Therapeutics Market Size Markets, 2022 & 2029
4.1.2 Immunosuppressors
4.1.3 Phosphodiesterase 5 Inhibitors - PHA
4.1.4 Endothelin Receptor Antagonists
4.1.5 Prostacyclin Analogues
4.1.6 Calcium Channel Blockers
4.1.7 Analgesics
4.1.8 Others
4.2 By Type - Global Scleroderma Therapeutics Revenue & Forecasts
4.2.1 By Type - Global Scleroderma Therapeutics Revenue, 2018-2023
4.2.2 By Type - Global Scleroderma Therapeutics Revenue, 2024-2029
4.2.3 By Type - Global Scleroderma Therapeutics Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Scleroderma Therapeutics Market Size, 2022 & 2029
5.1.2 Systemic
5.1.3 Localized
5.2 By Application - Global Scleroderma Therapeutics Revenue & Forecasts
5.2.1 By Application - Global Scleroderma Therapeutics Revenue, 2018-2023
5.2.2 By Application - Global Scleroderma Therapeutics Revenue, 2024-2029
5.2.3 By Application - Global Scleroderma Therapeutics Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Scleroderma Therapeutics Market Size, 2022 & 2029
6.2 By Region - Global Scleroderma Therapeutics Revenue & Forecasts
6.2.1 By Region - Global Scleroderma Therapeutics Revenue, 2018-2023
6.2.2 By Region - Global Scleroderma Therapeutics Revenue, 2024-2029
6.2.3 By Region - Global Scleroderma Therapeutics Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Scleroderma Therapeutics Revenue, 2018-2029
6.3.2 US Scleroderma Therapeutics Market Size, 2018-2029
6.3.3 Canada Scleroderma Therapeutics Market Size, 2018-2029
6.3.4 Mexico Scleroderma Therapeutics Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Scleroderma Therapeutics Revenue, 2018-2029
6.4.2 Germany Scleroderma Therapeutics Market Size, 2018-2029
6.4.3 France Scleroderma Therapeutics Market Size, 2018-2029
6.4.4 U.K. Scleroderma Therapeutics Market Size, 2018-2029
6.4.5 Italy Scleroderma Therapeutics Market Size, 2018-2029
6.4.6 Russia Scleroderma Therapeutics Market Size, 2018-2029
6.4.7 Nordic Countries Scleroderma Therapeutics Market Size, 2018-2029
6.4.8 Benelux Scleroderma Therapeutics Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Scleroderma Therapeutics Revenue, 2018-2029
6.5.2 China Scleroderma Therapeutics Market Size, 2018-2029
6.5.3 Japan Scleroderma Therapeutics Market Size, 2018-2029
6.5.4 South Korea Scleroderma Therapeutics Market Size, 2018-2029
6.5.5 Southeast Asia Scleroderma Therapeutics Market Size, 2018-2029
6.5.6 India Scleroderma Therapeutics Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Scleroderma Therapeutics Revenue, 2018-2029
6.6.2 Brazil Scleroderma Therapeutics Market Size, 2018-2029
6.6.3 Argentina Scleroderma Therapeutics Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Scleroderma Therapeutics Revenue, 2018-2029
6.7.2 Turkey Scleroderma Therapeutics Market Size, 2018-2029
6.7.3 Israel Scleroderma Therapeutics Market Size, 2018-2029
6.7.4 Saudi Arabia Scleroderma Therapeutics Market Size, 2018-2029
6.7.5 UAE Scleroderma Therapeutics Market Size, 2018-2029
7 Scleroderma Therapeutics Companies Profiles
7.1 F. Hoffmann-La Roche AG
7.1.1 F. Hoffmann-La Roche AG Company Summary
7.1.2 F. Hoffmann-La Roche AG Business Overview
7.1.3 F. Hoffmann-La Roche AG Scleroderma Therapeutics Major Product Offerings
7.1.4 F. Hoffmann-La Roche AG Scleroderma Therapeutics Revenue in Global Market (2018-2023)
7.1.5 F. Hoffmann-La Roche AG Key News & Latest Developments
7.2 Bristol-Myers Squibb Company
7.2.1 Bristol-Myers Squibb Company Company Summary
7.2.2 Bristol-Myers Squibb Company Business Overview
7.2.3 Bristol-Myers Squibb Company Scleroderma Therapeutics Major Product Offerings
7.2.4 Bristol-Myers Squibb Company Scleroderma Therapeutics Revenue in Global Market (2018-2023)
7.2.5 Bristol-Myers Squibb Company Key News & Latest Developments
7.3 Celgene Corporation
7.3.1 Celgene Corporation Company Summary
7.3.2 Celgene Corporation Business Overview
7.3.3 Celgene Corporation Scleroderma Therapeutics Major Product Offerings
7.3.4 Celgene Corporation Scleroderma Therapeutics Revenue in Global Market (2018-2023)
7.3.5 Celgene Corporation Key News & Latest Developments
7.4 Argentis Pharmaceuticals, LLC
7.4.1 Argentis Pharmaceuticals, LLC Company Summary
7.4.2 Argentis Pharmaceuticals, LLC Business Overview
7.4.3 Argentis Pharmaceuticals, LLC Scleroderma Therapeutics Major Product Offerings
7.4.4 Argentis Pharmaceuticals, LLC Scleroderma Therapeutics Revenue in Global Market (2018-2023)
7.4.5 Argentis Pharmaceuticals, LLC Key News & Latest Developments
7.5 Bayer AG
7.5.1 Bayer AG Company Summary
7.5.2 Bayer AG Business Overview
7.5.3 Bayer AG Scleroderma Therapeutics Major Product Offerings
7.5.4 Bayer AG Scleroderma Therapeutics Revenue in Global Market (2018-2023)
7.5.5 Bayer AG Key News & Latest Developments
7.6 Boehringer Ingelheim International GmbH
7.6.1 Boehringer Ingelheim International GmbH Company Summary
7.6.2 Boehringer Ingelheim International GmbH Business Overview
7.6.3 Boehringer Ingelheim International GmbH Scleroderma Therapeutics Major Product Offerings
7.6.4 Boehringer Ingelheim International GmbH Scleroderma Therapeutics Revenue in Global Market (2018-2023)
7.6.5 Boehringer Ingelheim International GmbH Key News & Latest Developments
7.7 Akashi Therapeutics
7.7.1 Akashi Therapeutics Company Summary
7.7.2 Akashi Therapeutics Business Overview
7.7.3 Akashi Therapeutics Scleroderma Therapeutics Major Product Offerings
7.7.4 Akashi Therapeutics Scleroderma Therapeutics Revenue in Global Market (2018-2023)
7.7.5 Akashi Therapeutics Key News & Latest Developments
7.8 Prometic Life Sciences, Inc.
7.8.1 Prometic Life Sciences, Inc. Company Summary
7.8.2 Prometic Life Sciences, Inc. Business Overview
7.8.3 Prometic Life Sciences, Inc. Scleroderma Therapeutics Major Product Offerings
7.8.4 Prometic Life Sciences, Inc. Scleroderma Therapeutics Revenue in Global Market (2018-2023)
7.8.5 Prometic Life Sciences, Inc. Key News & Latest Developments
7.9 Emerald Health Pharmaceuticals
7.9.1 Emerald Health Pharmaceuticals Company Summary
7.9.2 Emerald Health Pharmaceuticals Business Overview
7.9.3 Emerald Health Pharmaceuticals Scleroderma Therapeutics Major Product Offerings
7.9.4 Emerald Health Pharmaceuticals Scleroderma Therapeutics Revenue in Global Market (2018-2023)
7.9.5 Emerald Health Pharmaceuticals Key News & Latest Developments
7.10 Kadmon Holdings, Inc.
7.10.1 Kadmon Holdings, Inc. Company Summary
7.10.2 Kadmon Holdings, Inc. Business Overview
7.10.3 Kadmon Holdings, Inc. Scleroderma Therapeutics Major Product Offerings
7.10.4 Kadmon Holdings, Inc. Scleroderma Therapeutics Revenue in Global Market (2018-2023)
7.10.5 Kadmon Holdings, Inc. Key News & Latest Developments
7.11 Seattle Genetics, Inc.
7.11.1 Seattle Genetics, Inc. Company Summary
7.11.2 Seattle Genetics, Inc. Business Overview
7.11.3 Seattle Genetics, Inc. Scleroderma Therapeutics Major Product Offerings
7.11.4 Seattle Genetics, Inc. Scleroderma Therapeutics Revenue in Global Market (2018-2023)
7.11.5 Seattle Genetics, Inc. Key News & Latest Developments
7.12 Cytori Therapeutics, Inc.
7.12.1 Cytori Therapeutics, Inc. Company Summary
7.12.2 Cytori Therapeutics, Inc. Business Overview
7.12.3 Cytori Therapeutics, Inc. Scleroderma Therapeutics Major Product Offerings
7.12.4 Cytori Therapeutics, Inc. Scleroderma Therapeutics Revenue in Global Market (2018-2023)
7.12.5 Cytori Therapeutics, Inc. Key News & Latest Developments
7.13 Fibrocell Science, Inc.
7.13.1 Fibrocell Science, Inc. Company Summary
7.13.2 Fibrocell Science, Inc. Business Overview
7.13.3 Fibrocell Science, Inc. Scleroderma Therapeutics Major Product Offerings
7.13.4 Fibrocell Science, Inc. Scleroderma Therapeutics Revenue in Global Market (2018-2023)
7.13.5 Fibrocell Science, Inc. Key News & Latest Developments
7.14 Chemomab
7.14.1 Chemomab Company Summary
7.14.2 Chemomab Business Overview
7.14.3 Chemomab Scleroderma Therapeutics Major Product Offerings
7.14.4 Chemomab Scleroderma Therapeutics Revenue in Global Market (2018-2023)
7.14.5 Chemomab Key News & Latest Developments
7.15 Corbus Pharmaceuticals Holdings, Inc.
7.15.1 Corbus Pharmaceuticals Holdings, Inc. Company Summary
7.15.2 Corbus Pharmaceuticals Holdings, Inc. Business Overview
7.15.3 Corbus Pharmaceuticals Holdings, Inc. Scleroderma Therapeutics Major Product Offerings
7.15.4 Corbus Pharmaceuticals Holdings, Inc. Scleroderma Therapeutics Revenue in Global Market (2018-2023)
7.15.5 Corbus Pharmaceuticals Holdings, Inc. Key News & Latest Developments
7.16 Genkyotex
7.16.1 Genkyotex Company Summary
7.16.2 Genkyotex Business Overview
7.16.3 Genkyotex Scleroderma Therapeutics Major Product Offerings
7.16.4 Genkyotex Scleroderma Therapeutics Revenue in Global Market (2018-2023)
7.16.5 Genkyotex Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
NEED Help?
If you need any help or guidance, please feel free to call us.
USA : +1 (661) 636 6162
INDIA : +91 9325802062
or
Write us on : sales@kandjmarketresearch.com